Favorable safety profile, high overall response and complete response rates, and CAR T persistence observed in patients with relapsed or refractory follicular lymphoma
Experts across Fred Hutch gave their reads on what's to come in 2022, including technological advancements, new standards of care for people with cancer and progress against infectious disease.